SEC-sourced researchBeta

PLX

Protalix BioTherapeutics, Inc.

US markets

Data passport

CIK: 0001006281
Exchange: NYSE
Business activity: — · SIC 2836
Financial inputs: 6/6
Filing date: Sep 9, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 8:04 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

PLX · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	65,494,000.0000	Mar 18, 2026
December 2024	53,399,000.0000	Mar 18, 2026
December 2025	52,744,000.0000	Mar 18, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	52,744,000.0000	-6,604,000.0000	-11,993,000.0000	82,346,000.0000	34,116,000.0000	Mar 18, 2026
December 2024	53,399,000.0000	2,932,000.0000	8,674,000.0000	73,417,000.0000	30,206,000.0000	Mar 18, 2026
December 2023	65,494,000.0000	8,312,000.0000	-1,318,000.0000	—	—	Mar 18, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenues	$52.74M	December 2025	Mar 18, 2026	10-K
Previous period revenueRevenues	$53.4M	December 2024	Mar 18, 2026	10-K
Net incomeNetIncomeLoss	-$6.6M	December 2025	Mar 18, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$11.99M	December 2025	Mar 18, 2026	10-K
Total assetsAssets	$82.35M	December 2025	Mar 18, 2026	10-K
Total liabilitiesLiabilities	$34.12M	December 2025	Mar 18, 2026	10-K

New filings

Explore methodology ↗